Clinical Trials Logo

Newly Diagnosed clinical trials

View clinical trials related to Newly Diagnosed.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06409702 Not yet recruiting - Multiple Myeloma Clinical Trials

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Start date: May 2024
Phase:
Study type: Observational

The goal of this study is to evaluate sustained MRD negativity for one year in DKRD induction & consolidation therapy +/- ASCT in newly diagnosed high-risk multiple myeloma patients. It aims to evaluate the efficacy and safety of the combination regimen of Daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone (DKRD) +/- ASCT for the treatment of patients with newly diagnosed high-risk multiple myeloma. Participants will receive bortezomib based induction therapy for one cycle, and then DKRD induction for 3 cycles(+ASCT), DKRD consolidation for 2-4 cycles, and DKR maintenance treatment(adjusted according to MRD negativity after consolidation therapy)

NCT ID: NCT05287984 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

ZFCR/ZBR
Start date: March 22, 2022
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the long-term efficacy of BTK inhibitor Zanubrutinib monotherapy , sequential Zanubrutinib combined (Fludarabine, cyclophosphamide and rituximab /bendamustine and rituximab)FCR/BR regimen by a limited period of treatment for the newly diagnosed Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The investigators propose this combination will improve the MRD negative rate of patients with CR/CRi after treatment was significantly higher than that of FCR chemotherapy can be a time-limited regimen which will reduce the life-time therapy and benefit the patients.

NCT ID: NCT04254640 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

In this study, the investigators conducted a phase II trial that evaluated the efficacy and safety of cladribine in combination with modified CAG regimen (low-dose cytarabine and aclarubicin) in elderly patients with AML.